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Abstract
Over-expression of phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes (PED/PEA-15) causes
insulin resistance by interacting with the D4 domain of phospholipase D1 (PLD1). Indeed, the disruption of this association
restores insulin sensitivity in cultured cells over-expressing PED/PEA-15. Whether the displacement of PLD1 from PED/PEA-
15 improves insulin sensitivity in vivo has not been explored yet. In this work we show that treatment with a recombinant
adenoviral vector containing the human D4 cDNA (Ad-D4) restores normal glucose homeostasis in transgenic mice
overexpressing PED/PEA-15 (Tg ped/pea-15) by improving both insulin sensitivity and secretion. In skeletal muscle of these
mice, D4 over-expression inhibited PED/PEA-15-PLD1 interaction, decreased Protein Kinase C alpha activation and restored
insulin induced Protein Kinase C zeta activation, leading to amelioration of insulin-dependent glucose uptake. Interestingly,
Ad-D4 administration improved insulin sensitivity also in high-fat diet treated obese C57Bl/6 mice. We conclude that PED/
PEA-15-PLD1 interaction may represent a novel target for interventions aiming at improving glucose tolerance.
Citation: Cassese A, Raciti GA, Fiory F, Nigro C, Ulianich L, et al. (2013) Adenoviral Gene Transfer of PLD1-D4 Enhances Insulin Sensitivity in Mice by Disrupting
Phospholipase D1 Interaction with PED/PEA-15. PLoS ONE 8(4): e60555. doi:10.1371/journal.pone.0060555
Editor: Yulia Komarova, University of Illinois at Chicago, United States of America
Received October 19, 2012; Accepted February 27, 2013; Published April 9, 2013
Copyright:  2013 Cassese et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported in part by the European Community’s FP6 PREPOBEDIA (201681), the European Foundation for the Study of Diabetes (EFSD),
the Associazione Italiana per la Ricerca sul Cancro (AIRC) and by the Ministero dell’Universita` e della Ricerca Scientifica (grants PRIN and FIRB-MERIT). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: beguino@unina.it (FB); c.miele@ieos.cnr.it (CM)
. These authors contributed equally to this work.
Introduction
Type 2 Diabetes (T2D) is a chronic disorder associated with
vascular complications and increased risk of cardiovascular disease
[1]. Largely because of its contribution to cardio-vascular disease,
T2D is also associated to excess mortality. The prevalence of T2D
is increasing, making the identification of innovative therapeutic
targets an important priority in this field [2,3].
We recently described that overexpression of the PED/PEA-
15 gene is a common abnormality in T2D. PED/PEA-
15 mRNA and protein levels are highly expressed in skeletal
muscle and adipose tissues from individuals with T2D and their
First Degree Relatives (FDR) compared with euglycaemic
individuals [4,5]. In addition, high PED/PEA-15 levels strongly
correlate with resistance to insulin action in the lean mass of
these individuals [5]. Transgenic mice featuring ubiquitous over-
expression of Ped/pea-15 (TgPed/pea-15) exhibit decreased glucose
tolerance, due to a combination of fat and skeletal muscle
insulin resistance and reduced insulin secretion in response to
glucose. These mice develop diabetes when treated with a high
fat diet (HFD) [6]. In previous studies, we have shown that
PED/PEA-15 over-expression impairs both in vitro and in vivo
insulin-stimulated glucose disposal through the interaction with
the D4 domain of the Phospholipase D1 (PLD1). Both PLD1
stability and protein expression are increased in cells overex-
pressing PED/PEA-15, as well as the PLD1-dependent activa-
tion of the protein kinase Calpha (PKCalpha) [6–8]. This, in
turn, causes inhibition of the insulin-mediated PKCzeta activity,
and decreased insulin-induced GLUT4 translocation to the
plasma membrane [6–8]. In addition, we showed that in
cultured muscle cells stably overexpressing PED/PEA-15, the
expression of D4 displaces the interaction of PED/PEA-15 with
PLD1. This effect reduces basal PKCalpha activity and restores
the insulin-stimulated glucose disposal mediated by PKCzeta
[9].
In the present work, we have used a recombinant adenoviral
vector containing the human D4 cDNA (Ad-D4) to establish
whether the dissociation of PLD1 from PED/PEA-15 improves
whole body glucose tolerance, in both TgPed/pea-15 and obese high
fat-fed C57BL6 mice.
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Materials and Methods
Ad-D4 Cloning and Preparation
The Ad-D4 vector was obtained as previously described by [10].
Briefly, human D4 cDNA was introduced at the HindIII and
KpnI sites in pAd-Track-CMV shuttle vector, which contains two
distinct gene cassettes for the simultaneous expression of the target
protein and of the Green Fluorescent Protein (GFP) (kindly
provided by Dr. Bert Vogelstein). The resulting pAd-Track-CMV-
D4 plasmid was then linearized by PmeI and transformed with the
adenoviral pAdEasy-E1 vector in BJ5183 EC cells. The resulting
recombinant vector was linearized with PacI and transfected in
HEK293 cells using lipofectamine reagent (Invitrogen). 24 h after
transfection, cells were overlaid with agarose to permit isolation of
individual virus plaques, and visible plaques were selected and
expanded after 7–10 days from transfection. Viruses were then
purified from HEK293 cells by freeze/thaw cycles and cesium
chloride step gradients, and aliquots of the obtained recombinant
adenoviruses were frozen and stored at 280uC.
Cell Culture Procedures, Adenoviral Infection and 2-[1-
3H]deoxy-d-glucose Uptake in vitro
Parental L6 rat skeletal muscle cells (L6Wt) and L6 cells over-
expressing PED/PEA-15 (L6PED/PEA-15) were grown in
DMEM supplemented with 10% (vol./vol.) FBS, 2 mmol/l L-
glutamine and antibiotics. L6 myotubes were allowed to differen-
tiate as described previously [11]. Differentiated L6 myotubes
were then infected with Ad-D4 or Ad-GFP vector by infections
with different concentrations of the virus. Subsequent experiments
were performed 48 h after initial addition of virus. Cell lysates and
immunoblotting were carried out as described previously [11]. 2-
DG uptake was measured as reported previously [11].
Mouse models. TgPed/pea-15 mice were backcrossed for 8
generations on the C57/Bl6 background. 3–6 months old male
and female TgPed/pea-15 mice and their normal littermates (wild
Figure 1. D4 mRNA expression in TgPed/pea-15 mice. D4 mRNA expression was determined by quantitative Real Time RT-PCR analysis of total
RNA isolated from liver (A), pancreas (B), and tibialis skeletal muscle tissue (C) of TgPed/pea-15 mice at one week post Ad-D4 or Ad-GFP infection.
GAPDH was used as housekeeping gene. mRNA levels in Ad-D4 treated TgPed/pea-15 mice are relative expression units to those in Ad-GFP treated
TgPed/pea-15 mice used as control (mean 6 SEM; n = 3). ***p,0.001 vs Ad-GFP treated TgPed/pea-15.
doi:10.1371/journal.pone.0060555.g001
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type; WT) were used for all studies. Mice were housed in the
animal facilities for at least one week before experiments. All
procedures and euthanasia were conducted in accordance with
adoption of Institutional Animal Care and Utilization Committee
(Ministero della Salute, Dipartimento della Sanita` Pubblica
Veterinaria, della Sicurezza Alimentare e degli Organi Collegiali
per la Tutela della Salute, Direzione Generale della Sanita`
Animale e dei Farmaci Veterinari). The ethics committee of the
Ministero della Salute, Dipartimento della Sanita` Pubblica
Veterinaria, della Sicurezza Alimentare e degli Organi Collegiali
per la Tutela della Salute Direzione Generale della Sanita`
Animale e dei Farmaci Veterinari approved this study. Mice were
housed one per cage on a 12-h light/dark cycle (lights on 0600–
1800) and fed water and standard diet (11% calories from fat;
Research Diets formulas D12328; Research Diets, Inc., New
Brunswick, N.J) ad libitum (AL). For the high fat diet (HFD), 2-
month-old WT (n= 12) mice were fed with a 60 kcal% fat content
(Research Diets formulas D12331; Research Diets, Inc., New
Brunswick, N.J.) ad libitum for 11 weeks.
Ad-D4 infection in vivo. The day of adenoviral injection,
mice were anaesthetized by i.p. administration of 2,2,
2-tribromoethanol (Sigma Aldrich), and then the Ad-D4 or the
control Ad-GFP vectors were i.v. injected into the tail vein at the
final concentration of 261012 vp/kg. Mice were euthanized after
6 days from infection, and their tissues were quickly collected and
frozen in dry-ice.
Lysate preparation, Immunoprecipitation (IP) and
Western Blot (WB). Mice were fasted overnight, anesthetized,
and injected i.p. with saline or insulin (10 U/kg body weight). Ten
min after injection, skeletal muscle tissues (quadriceps, gastro-
cnemious and tibialis) were removed and frozen in dry ice. Tissues
homogenates and cell lysates were separated by SDS-PAGE and
analyzed by western blot as previously described [12]. For each IP
experiment about 0.5–1 mg of skeletal muscle protein lysate was
precleared with 20 ml of pre-immune serum at 4uC for 30 min and
then incubated with 1.5 mg of anti-PED-PEA15 or anti-PLD1
antibody O.N. at 4uC. After incubation, 40 ml of protein A
sepharose (Invitrogen) in a 1:1 mixture of protein A sepharose and
Lysis Buffer were added to the IP samples. Purified interacting
complex was released from protein A sepharose beads by boiling
in SDS-PAGE sample buffer and resolved on SDS-PAGE.
Samples were then subjected to WB analysis. Membranes were
firstly probed with antibodies to PED/PEA-15 antiserum, PLD1
(Cell Signalling Technology), phospho-PKCalpha, PKCalpha
(Millipore), phospho-PKCzeta, PKCzeta, Tubulin (Santa Cruz
Biotech Inc), and GFP-peptide living colors (BD Transduction
Laboratories), and then with secondary mouse or rabbit antibodies
(GE Healthcare) before detection of the signal with ECL plus (GE
Healthcare).
Real time quantitative PCR. Total RNA extraction, cDNA
synthesis and Real Time quantitative PCR were performed as
described [13]. Primer sequences are as follows: D4 F: 59-
agtccatccacgccgttac-39; D4 R: 59-tcctctgggcaatggcatcg-39;
GAPDH F: 59-gccttccgtgttcctacc-39; GAPDH R: 59-agagtgg-
gagttgctgttg-39.
PLD assay in vitro. PLD activity assays were carried out
using the in vitro head group release assay and the in vivo
transphosphatidylation assay as described previously [8]. Briefly,
skeletal muscle homogenates were centrifuged at 10,0006g for
5 min, and their supernatants were designated as crude mem-
branes. PLD1 activity was then determined by measuring the
transphosphatidylation activity in the presence of butanol.
Recombinant ADP-ribosylation factor 1 (ARF1) and Ras homolog
gene family, member A (RhoA) were added to the samples and
were activated using 10 mM of Guanosine 59-[c-thio]-triphosphate
(GTP[S]). Lipid products were extracted and then separated on a
Silica Gel 60 TLC plate with chloroform/methanol/acetic acid
(13:3:1 by vol.) as the developing solvent. The spots corresponding
to [14C] phosphatidyl-butanol were determined by autoradiogra-
phy and their radioactivity was counted to obtain analytical values.
Metabolite assays. Blood glucose levels were measured with
glucometers (OneTouch Ultra2, LifeScan); insulin was measured
by radioimmunoassay with rat insulin as standard (Linco
Research). Fasting plasma free fatty acids were measured with
the Wako NEFA C kit (Wako Chemicals), and tricylglycerol was
measured with the Infinity triglyceride reagent (Sigma Aldrich).
Glucose and insulin tolerance, and measurement of 2-[1-
3H] deoxy-D-glucose uptake. Glucose tolerance tests (GTTs)
and insulin tolerance tests (ITTs) were measured as described [13].
For analyzing glucose utilization, an intravenous injection of 1 mCi
of the nonmetabolizable glucose analog 2-[1-3H]deoxy-d-glucose
(2-DG) (Amersham Pharmacia Biotech) and an intraperitoneal
injection of insulin (0.75 mU/g body wt) were administered to
random fed mice. The specific blood 2-DG clearance was
Table 1. Metabolic characteristics of TgPed/pea-15 mice.
Metabolic parameters Wild Type TgPed/pea-15
Vehicle Vehicle Ad-GFP Ad-D4
Fasting glucose (mg/dl) 81.867.0 99.663.6a 97.369.7b 79.867.6e,g
Fed glucose (mg/dl) 126.362.0 140.966.5a 148.968.6b 117.5616.2f,h
Fasting insulin (ng/ml) 0.3260.03 0.4560.05a 0.5060.06b 0.2860.06f,h
Fasting NEFA (mEq/l) 0.6260.12 0.8160.05a 0.8560.08b 0.5660.04f,h
Fasting Triacylglycerol (mg/ml) 0.2360.03 0.2760.02 0.3660.03b,c 0.3860.03d,f
Data are means 6 SEM of determinations in at least 10 mice per group. Vehicle TgPed/pea-15 mice vs. Vehicle Wild Type mice;
aP,0.001. Ad-GFP TgPed/pea-15 mice vs. Vehicle Wild Type mice;
bP,0.001. Ad-GFP TgPed/pea-15 mice vs. Vehicle TgPed/pea-15 mice;
cP,0.001. Ad-D4 TgPed/pea-15 mice vs. Vehicle Wild Type mice;
dP,0.001. Ad-D4 TgPed/pea-15 mice vs. Vehicle TgPed/pea-15 mice;
eP,0.01 and
fP,0.001. Ad-D4 TgPed/pea-15 mice vs. Ad-GFP TgPed/pea-15 mice;
gP,0.01 and
hP,0.001.
doi:10.1371/journal.pone.0060555.t001
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Figure 2. Glucose tolerance, insulin sensitivity and insulin secretion in TgPed/pea-15 mice. A) Glucose Tolerance Test (GTT) and (B) Area
Under the Curve (AUC) glucose in TgPed/pea-15 mice treated with vehicle (black square and column) or after infection with Ad-GFP (dark grey square
and column) or with Ad-D4 (light grey square and column), and wild type mice (Wt, white circle and column) used as controls. C) Insulin Tolerance
Test (ITT) and (D) Area Under the Curve (AUC) glucose in TgPed/pea-15 mice treated with vehicle (black square and column) or after infection with Ad-
GFP (dark grey square and column) or with Ad-D4 (light grey square and column), and wild type mice (Wt, white circle and column) used as controls.
For each experiment, values are expressed as means6 SEM of determinations in at least eight mice per group. ***p,0.001 vs Wt. E) Glucose-induced
insulin secretion in 6 TgPed/pea-15 mice treated with vehicle (black square and column) or after infection with Ad-GFP (dark grey square and column) or
Adenoviral Gene Transfer of PLD1-D4
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determined with 25-ml blood samples (tail vein) obtained 1, 15, and
30 min after injection as previously reported [13]. Quadriceps,
soleus and tibialis skeletal muscles and perigonadal adipose tissue
were removed 30 min after the injections. Glucose utilization
index was determined by measuring the accumulation of
radiolabeled compound [13]. The amount of 2-DG-6 phosphate
per milligram of protein was then divided by the integral of the
concentration ratio of 2-DG to the measured unlabeled glucose.
Figure 3. Protein interaction of PED/PEA-15 with PLD1 and PLD1 activity in TgPed/pea-15 mice. A) Immunoblots of total protein lysates
from skeletal muscle homogenates of wild type (Wt) and TgPed/pea-15 mice at one week post Ad-D4 or Ad-GFP infection. The blots were probed with
anti-PLD1, anti-PED/PEA-15 and anti-Tubulin antibodies. PI stands for pre-immune serum. B) Immunoblots of immunoprecipitated from skeletal
muscle homogenates of wild type (Wt) and TgPed/pea-15 mice. IP were performed using the anti-PED/PEA-15 antibody as described in Experimental
Procedures. The upper blot was probed with anti-PLD1 antibody, while the bottom blot was striped and then probed with anti-PED/PEA-15 antibody.
C) PLD1 activity was analyzed in skeletal muscle homogenates from wild type (Wt) and TgPed/pea-15 mice by measuring the transphosphatidyl-butanol
levels as described in Materials and methods. The autoradiography shown is representative of three independent assays. D) The bar graph represents
the densitometric quantization of the spots in three experiments in triplicate. ***p,0.001 vs. Wt. E) Immunoblots of whole lysates from skeletal
muscle homogenates of TgPed/pea-15 mice at one week post Ad-D4 or Ad-GFP infection or PBS injection (vehicle). The upper blot was probed with
anti-GFP antibody, while the bottom blot was striped and then probed with anti-tubulin antibody. F) Immunoblots of immunoprecipitated from
skeletal muscle homogenates of TgPed/pea-15 mice at one week post Ad-D4 or Ad-GFP infection. IP were performed using the anti-PED/PEA-15
antibody. The upper blot was probed with anti-PLD1 antibody, while the bottom blot was striped and then probed with anti-PED/PEA-15 antibody.
doi:10.1371/journal.pone.0060555.g003
with Ad-D4 (light grey square and column), and wild type mice (Wt, white circle and column). Data points represent the means 6 SEM of
determinations in five mice per group. ***p,0.001, t = 3 and t = 30 vs t = 0; #p,0.001, TgPed/Pea-15 t = 0 vs Wt t = 0.
doi:10.1371/journal.pone.0060555.g002
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Glucose utilization indexes were expressed as picomoles per
milligram of protein per minute.
Statistical analysis. Data are expressed as means 6 SEM
and statistical significance between groups was analyzed by 2-
tailed Student’s t-test or analysis of variance (ANOVA) as
appropriate. P values of ,0.05 were considered statistically
significant. The total AUC and the inverse AUC for glucose
response during GTT and ITT were calculated as [12].
Results
Ad-D4 Transduction in vitro and in vivo. Untrasfected L6
skeletal muscle cells (L6Wt) and L6 cells over-expressing PED/
PEA-15 (L6PED/PEA-15) were transduced with 4 different clones of
Ad-D4 vector. D4 levels were indirectly evaluated by measuring
the Green Fluorescent Protein (GFP) expression, being the GFP
expressed by the Ad-D4 vector. At 48 hours post-transduction,
GFP production was detectable in both L6Wt and L6PED/PEA-15
cells transfected with clone 1; lower levels were detectable when
the cells were infected with clones 2, 3 and 4 (Figure S1a and b).
Then, the biological activity of Ad-D4 vector was analyzed by
measuring insulin-induced glucose uptake in the insulin resistant
L6PED/PEA-15 cells transduced with clone 1 or with the adenoviral
vector expressing only the GFP (Ad-GFP) as a control. Transduc-
tion of L6PED/PEA-15 cells with Ad-D4 induced a 2-fold increase of
the 2-DG uptake compared to L6PED/PEA-15 cells which were not
trasduced (NT) or to L6PED/PEA-15 transduced with Ad-GFP
(Figure S1c), indicating that Ad-D4 transduction restores insulin
sensitivity in L6PED/PEA-15 cells. D4 was then transduced in vivo by
injecting TgPed/pea-15 mice with Ad-D4 or Ad-GFP vector. D4
mRNA expression was measured in different tissues upon 6 days
after the adenoviral delivery. D4 mRNA resulted highly expressed
in liver, pancreas as well as in tibialis skeletal muscle of the Ad-D4
injected transgenic mice compared to the Ad-GFP injected control
mice (Figure 1a, b, c).
Ad-D4 treatment improves glucose homeostasis and
metabolic parameters in TgPed/pea-15 mice. We then aimed
at evaluating the effect of D4 on glucose tolerance. As previously
reported [6], TgPed/pea-15 mice exhibited increased fasting and
Figure 4. Effect of D4 on PKCalpha and zeta activation in TgPed/pea-15 mice. PKCalpha (A) and zeta (B) activations were determined in the
skeletal muscle tissues from TgPed/pea-15 mice at one week post Ad-D4 or Ad-GFP infection. TgPed/pea-15 or wild type (Wt) mice injected with PBS
(vehicle) were used as control. For the experiment, mice were fasted over night and then i.p. injected or not with insulin (10 U/kg body weight)
10 min before determination. A) The bar graph represents the densitometric quantization of phospho-PKCalpha in three independent immunoblots.
***p,0.001 vs. Wt. B) The corresponding blots show the levels of PKCzeta (total and phosphorilated forms) and tubulin in mice as indicated. Blots are
representative of three independent experiments.
doi:10.1371/journal.pone.0060555.g004
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random fed blood glucose levels and fasting insulin and NEFA
concentrations (Table 1). Furthermore, glucose loading (2 g/kg
body weight) made these mice significantly more hyperglycaemic
than control mice during the following 120 min (Fig. 2a, b). When
injected with the Ad-D4 vector, TgPed/pea-15 mice showed fasting
and random fed blood glucose levels comparable to those of
control mice (Table 1), and exhibited normal glucose tolerance
after GTT (Figure 2a, b). The Ad-D4 treatment was also able to
lower fasting insulin and NEFA concentrations in
TgPed/pea-15 mice, achieving values similar to those of control
mice (Table 1). No improvement of either fasting and random fed
blood glucose levels, fasting insulin and NEFA levels, and glucose
tolerance were observed when TgPed/pea-15 mice were treated with
the Ad-GFP (Table 1; Figure 2a, b). TgPed/pea-15 mice injected
with both the Ad-D4 and Ad-GFP showed a slight increase in
fasting triacyglycerol levels when compared to both the control
Figure 5. Glucose uptake in skeletal muscle tissues of TgPed/pea-15 mice. Ex vivo Glucose uptake into gastrocnemius (A), tibialis (B) and
quadriceps (C) skeletal muscle of TgPed/pea-15 mice treated with vehicle (black column) or after infection with Ad-GFP (light grey column) or with Ad-
D4 (dark grey column), and wild type mice (Wt, white column) used as controls. Values are expressed as means 6 SEM of determinations in at least
five mice per group. ***p,0.001 vs Wt.
doi:10.1371/journal.pone.0060555.g005
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and TgPed/pea-15 mice before adenoviral delivery (Day 0; Table 1),
suggesting that this effect was not due to D4 transduction.
Ad-D4 treatment improves insulin sensitivity and
secretion in TgPed/pea-15 mice. To verify whether the bene-
ficial effect of Ad-D4 treatment on glucose tolerance is also
accompanied by an improvement of whole body insulin
sensitivity, we performed insulin tolerance test (ITT). Following
i.p. injection of insulin (0.75 U/kg body weight) a strong
reduction of the hypoglycaemic response was observed in
untreated TgPed/pea-15 mice compared to controls (Fig. 2c, d).
On the other hand, insulin was able to lower glucose levels
during ITT in the Ad-D4 treated TgPed/pea-15 mice to levels
comparable to control mice, but not in the Ad-GFP treated
TgPed/pea-15 mice (Fig. 2c, d). We then evaluated glucose-
induced insulin secretion. In control mice, a 2.5 fold increase
in insulin secretion was observed 3 min after glucose injection,
with levels remaining higher than baseline for up to 30 min,
indicating a second-phase response (Fig. 2e). In contrast, the
acute first-phase insulin secretory response to glucose and the
late second-phase response were completely abolished in
TgPed/pea-15 mice (Fig. 2e). Interestingly, Ad-D4 treatment
improved the insulin secretion in response to glucose loading
in TgPed/pea-15 mice, while Ad-GFP treatment did not (Fig. 2e).
Thus, Ad-D4 administration ameliorated both insulin sensitivity
and secretion in TgPed/pea-15 mice, restoring a normal glucose
homeostasis.
Ad-D4 treatment re-establishes insulin sensitivity in
skeletal muscle tissue of TgPed/pea-15 mice. We then eval-
uated the expression of both PED/PEA-15 and PLD1 and
whether PED/PEA-15/PLD1 interaction also occurs in vivo. To
this aim, we performed western blot analysis to evaluate the
total protein amount and co-immunoprecipitation experiments
in tibialis skeletal muscle extracts from TgPed/pea-15 and control
mice (Wt). As expected, we found that both PED/PEA-15 and
PLD1 protein levels were increased in tibialis skeletal muscle
extracts from Ad-GFP treated TgPed/pea-15 compared to control
mice (Wt). PLD1 levels were reduced by D4 expression in
TgPed/pea-15 mice, wilst D4 did not alter PED/PEA-15
Figure 6. Insulin sensitivity in STD and HFD fed C57BL/6 mice.
A) Immunoblots of total protein lysates from skeletal muscle
homogenates of C57BL/6 mice fed with standard (STD) or high fat
(HFD) diets after infection with Ad-GFP or with Ad-D4. The upper blot
was probed with anti-GFP antibody, while the bottom blot was probed
with anti-Tubulin antibody. B) Insulin Tolerance Test (ITT) and (C) Area
Under the Curve (AUC) glucose in C57BL/6 mice fed with standard (STD,
square) or high fat (HFD, circle) diets after infection with Ad-GFP (white
and dark gray) or with Ad-D4 (black and light gray). For each
experiment, values are expressed as means 6 SEM of determinations
in at least eight mice per group. ***p,0.001 vs Ad-GFP treated STD fed
C57BL/6 mice. ##p,0.01, vs Ad-GFP treated HFD fed C57BL/6 mice.
doi:10.1371/journal.pone.0060555.g006
Table 2. Metabolic characteristics and food intake of HFD
and STD fed C57Bl/6 mice.
Food Intake Weight Fasting Glucose
(g/day) (g) (mg/dl)
STD Baseline 3.3560.20 18.761.9 7368
w11 4.2961.10 27.964.4 82616
w11 Ad-GFP n.a. 28.362.7 84.369.2
w11 Ad-D4 n.a. 28.561.7 82.9613.1
HFD Baseline 2.9760.61 18.362.2 68610
w11 4.0060.90 40.465.2b 120615a
w11 Ad-GFP n.a. 41.261.9c 117622c
w11 Ad-D4 n.a. 41.662.3d 102613e
Mice were analysed as described under Materials and Methods. Data are the
means6 SEM of determinations in 12 STD and 12 HFD fed C57Bl/6 mice on the
following conditions: baseline, upon 11 week of diet (w11), upon w11 treated
with Ad-GFP and upon w11 treated with Ad-D4. HFD w11 vs. STD w11 mice;
ap,0.01 and
bp,0.001; HFD w11 Ad-GFP vs. STD w11 mice;
cp,0.001; HFD w11 Ad-D4 vs. STD w11 mice;
dp,0.001; HFD w11 Ad-D4 vs. HFD w11 Ad-GFP mice;
ep,0.001; n.a., not available.
doi:10.1371/journal.pone.0060555.t002
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expression (Figure 3a). PED/PEA-15 interacted with PLD1 in
the tibialis muscles of both Wt and transgenic mice, and this
interaction was increased by 4-fold in TgPed/pea-15 mice
(Figure 3b). PLD1 activity was also significantly increased in
muscle homogenates from TgPed/pea-15 mice (Figure 3c, d).
Following Ad-D4 infection, D4 expression was confirmed by
the detection of a 28 KDa protein corresponding to GFP in the
tibialis muscle extracts from both Ad-GFP and Ad-D4 infected
transgenic mice (Figure 3e). The amount of PLD1 protein co-
immunoprecipitated with PED/PEA-15 protein was significantly
reduced in the tibialis muscle homogenate from the
TgPed/pea-15 mice injected with Ad-D4 (Figure 3f). We further
investigated whether the ability of D4 to prevent PED/PEA-15/
PLD1 interaction in these samples restores PKCalpha and zeta
activation. Basal PKCalpha phosphorylation was increased in
the tibialis muscle from TgPed/pea-15 mice injected with either
vehicle or Ad-GFP when compared to that of Wt mice, while
Ad-D4 treatment lowered PKCalpha activity to levels similar to
those of control mice (Figure 4a). In addition, whilst insulin
failed in inducing PKCzeta phosphorylation in the muscle of
TgPed/pea-15 mice injected with either vehicle or Ad-GFP,
insulin-induced PKCzeta activation following Ad-D4 infection
was restored to levels comparable to those of control mice
(Figure 4b). Finally, insulin-stimulated glucose transport was
strongly reduced in the gastrocnemious as well as in the tibialis
and quadriceps skeletal muscle of TgPed/pea-15 mice injected with
either vehicle or Ad-GFP compared to control mice, whilst
infection of Ad-D4 resulted in a marked increase of the glucose
uptake to levels comparable to those of controls (Figure 5a, b,
c). Thus, Ad-D4 delivery fully restored insulin sensitivity in
TgPed/pea-15 mice.
Ad-D4 treatment improves insulin sensitivity in obese
C57BL/6 mice. Recent observation by Ungaro P. et al dem-
onstrated that Ped/pea-15 mRNA expression is increased by 2-fold
in the tibialis skeletal muscle tissue of 6 month old diet-induced
obese C57BL/6 mice [14]. Therefore, we investigated if Ad-D4
may improve insulin sensitivity also in this model. To this aim, Ad-
D4 was injected in two groups of C57BL/6 mice which were fed
either a standard isocaloric diet (STD) or an highly palatable high
fat diet (HFD). HFD-fed mice reached a 40% increase of the body
weight at the end of the 11 weeks of diet regimen when compared
to STD-fed mice and their fasting glycaemia was significantly
increased as well (Table 2). D4 levels, measured indirectly by GFP
detection, were comparable in tibialis skeletal muscle extracts from
C57Bl/6 mice fed with either STD or HFD (Figure 6a). ITT
studies revealed that in the HFD-fed mice treated with Ad-GFP
glucose levels remained higher during the entire length of the
tolerance test, indicating the presence of insulin resistance in these
mice (Figure 6b, c). At variance, Ad-D4 treatment strongly
improvedinsulin sensitivity in the obese C57Bl/6 mice, as shown
by a significant decreased of their blood glucose levels within the
120 min of the test (Figure 6b, c). On the other hand, Ad-D4
treatment did not affect insulin sensitivity of lean STD-fed mice
(Figure 6b, c).
Discussion
Type 2 Diabetes imposes a major burden on public health at the
global level [2]. The pathogenetic heterogeneity of this disorder
has long being challenging the development of effective treatment
strategies as well as the identification of innovative targets [3,15].
We have previously identified PED/PED-15 as a gene that
contributes to Type 2 Diabetes susceptibility in humans [4,5]. In
different populations of Type 2 diabetics as well as in the first
degree relatives of these individuals [4,5], PED/PEA-15 was found
to be commonly over-expressed in skeletal muscle as well as in
white adipose tissues and in peripheral blood leukocytes.
Furthermore, PED/PEA-15 protein levels negatively correlate to
insulin sensitivity in offsprings of Type 2 diabetics [5]. Studies in
cellular and animal models over-expressing PED/PEA-15 have
shown that increased PED/PEA-15 expression impairs both
insulin action and secretion [4,6,7,13]. While the molecular bases
of PED/PEA-15 overexpression have not yet been completely
clarified, PED/PEA-15 interaction with PLD1 was identified as a
major mechanism responsible for reduced glucose tolerance in
animals and humans expressing high PED/PEA-15 levels [8].
Accordingly, we have previously shown that dissociation of PLD1
from PED/PEA-15 ameliorates insulin sensitivity in cultured
muscle cells stably overexpressing PED/PEA-15 by reducing basal
PKCalpha activity and restoring PKCzeta dependent insulin-
stimulated glucose disposal [9]. PCKalpha and PKCzeta are
members of the PKC superfamily and play a different role in the
regulation of insulin signal transduction. Indeed, activation of the
atypical PKC isoforms zeta by insulin is required for the regulation
of glucose uptake in adipocytes and in skeletal muscle cells [16,17],
whilst the classical PKCalpha isoform acts both in vitro and vivo as
an endogenous negative feedback inhibitor of insulin signaling by
modulating IRS1, PI3K and PKCzeta and lambda as well [18]. In
previous work, we showed that blocking PKCalpha either by a
specific antisense or by chemical inhibitors as well as the
pharmacological inhibition of PLD1 permits recovery of the
glucose uptake into muscle and fat cells over-expressing PED/
PEA-15 [7,9]. The effects of PED/PEA-15 on insulin secretion are
also reverted by PKCzeta overexpression [13]. However, overex-
pression of PKCzeta or inhibition of PLD1 or PKCalpha
expression/activity are unlikely to represent feasible pharmaco-
logical strategies to improve insulin sensitivity and/or secretion
due to the pleiotropic roles of these proteins in the regulation of
key events in cellular physiology. Furthermore, the existing non–
isoform-specific PKC inhibitors interact with other ATP binding
kinases and therefore display toxic and severe side effects in vivo.
[19–21]. Alternatively, the inhibition of the interaction between
PED/PEA-15 and PLD1 and the development of strategies to
convey molecules within the cell that achieve this inhibition may
represent an innovative and highly selective approach to improve
both insulin sensitivity and beta cell function in vivo.
In the present work, we investigated the effect of the PLD1 D4
peptide in vivo, using a recombinant adenoviral vector to transduce
D4 cDNA (Ad-D4). Adenoviral vectors are very well characterized
under the pharmacological, toxicological and pharmacokinetic
profile. Many studies in different mouse models demonstrated that
they are able to revert phatological phenotype of metabolic
disorders like PKU [22] and FH [23]. We have shown that Ad-D4
delivery in mice was well tolerated and led to a widespread
expression of the D4 peptide in several tissues, such as skeletal
muscle, liver and pancreas. Importantly, we found that the D4
expression restored whole body glucose homeostasis and normal-
ized both fasting and random fed glucose levels as well as fasting
insulin and FFA concentration in the TgPed/pea-15 mice. An
increase in fasting serum triglycerol levels and a slight decrease
in body weight (data not shown) were observed one week after the
adenoviral delivery in both the Ad-D4 and the Ad-GFP treated
transgenic mice and interpreted as side effects caused by
recombinant adenovirus infection. We also show that D4
expression significantly improved both insulin sensitivity and
pancreatic beta-cells insulin secretion in the TgPed/pea-15 mice,
indicating that D4 improvement of glucose tolerance involves
actions on insulin target tissues and on pancreatic beta-cells. D4
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administration in vivo is able to restore basal insulin levels and to
improve insulin secretion upon glucose loading. In particular, we
observed in Ad-D4 treated TgPed/pea-15 mice that the secretion of
the hormone was slightly increased 3 minutes after glucose loading
compared to control mice. Interestingly, this secretory profile is
associated with a reduction of the blood glucose levels observed
upon 30 minutes from glucose injection during glucose tolerance
test, in the Ad-D4 treated TgPed/pea-15 mice compared to control
mice (Figure 2a). Lower glucose levels may be thus responsible for
a reduced requirement of hormone release and may explain the
difference in the second-phase response in the Ad-D4 treated
TgPed/pea-15 mice. Finally, we confirmed that the over-expression
of the D4 peptide in these mice displaced the interaction of PED/
PEA-15 with PLD1. After Ad-D4 treatment, the total protein
levels of PLD1 in the skeletal muscles from TgPed/pea-15 mice were
similar to those measured in control mice. This, in turns, reduced
basal PKCalpha activation, restoring the insulin-stimulated
PKCzeta activation and ameliorating glucose disposal in tibialis
skeletal muscle. Other molecules implicated in the transduction of
insulin signal, such as PI 3-kinase and Akt, apparently, were not
affected by the D4 expression (data not shown). These data
indicate that, in vivo, forced D4 expression impairs PED/PEA-15
binding to PLD1 and may represent a novel strategy to improve
insulin sensitivity in skeletal muscle. Together with the positive
effect of D4 expression on glucose-induced insulin secretion, this
may contribute to the amelioration of whole body glucose
homeostasis. Recently, Doti N. et al have shown that the use of
a restricted D4 domain, named D4alpha, or the use of short PLD1
peptides that could mimic PED/PEA-15 binding interface can be
used as antagonists to prevent the association of PLD1 from PED/
PEA-15 [24]. This study provided thus new short, selective and
efficient PED/PEA-15-PLD1 antagonists alternative to the D4
that could be transduced to the cells and tissues by adenoviral gene
delivery approach. The possibility to vehiculate these smaller
compounds and to evaluate their efficacy in vivo is currently under
investigation in our laboratory.
Next, we have investigated whether over-expression of the D4
peptide is also effective in improving insulin sensitivity in a mouse
model of obesity and diabetes. Indeed, recent work from our group
has shown over-expression of Ped/pea-15 mRNA in the tibialis
skeletal muscle of C57Bl/6 mice in which obesity is induced by
high fat (HFD) feeding [14]. We now report that the D4 treatment
improves insulin sensitivity in HFD induced obese C57BL/6 mice,
with no effect on the body weight of animals. These findings
suggest that i., the efficacy of D4 treatment is not limited to the
TgPed/pea-15 mouse model of insulin resistance; and i.i., Ped/pea-15
over-expression may play a role in the onset and/or maintenance
of insulin resistance during diet-induced obesity.
Whether the efficacy of the D4 treatment in the obese mouse
model is exclusively due to PED/PEA-15 increased expression
occurring as a consequence of the HFD or is caused also by a
different modulation of PLD1 activity still needs to be clarified.
PLD1 is a pleiotropic enzyme implicated in several cellular
pathways, including signal transduction, membrane trafficking,
and the regulation of proliferation and survival [25], and, in
addition to PED/PEA-15, many members of the ADP-ribosylation
factor (ARF) [26,27], PKCalpha [28] and small G protein RhoA
[29,30] were identified as PLD interactors and/or activators.
Thus, the possibility that the D4 peptide modulates in vivo PLD1
activity also by PED/PEA-15-independent mechanisms cannot be
excluded.
In conclusion, our findings have established the in vivo efficacy of
a gene delivery treatment aiming at improving insulin sensitivity
by interfering with the interaction between PED/PEA-15 and
PLD1. Our results also suggest that this strategy is effective in a
mouse model of obesity-induced insulin resistance, and support
further efforts aimed at generating novel molecules that interfere
with PED/PEA-15 and/or PLD1 functions mimicking D4 peptide
action.
Supporting Information
Figure S1 Expression of D4 peptide and 2-DG uptake in
L6Wt and L6PED/PEA-15 cells. A) GFP expression was
determined in lysates from L6Wt and L6PED/PEA-15 cells after
48h from transduction with Ad-D4 clones 1, 2, 3 and 4. GFP
expression was compared with L6PED/PEA-15 transfected with
Ad-GFP. Not transfected (NT) cells were used as control. B)
Insulin-induced glucose uptake into L6Wt and L6PED/PEA-15
cells not transfected (NT) or transfected with Ad-GFP or Ad-D4
vector. Values for each cell type represent the fold induction upon
insulin stimulation over their own basal and are expressed as
means 6 SEM of determinations in 3 independent experiments.
***p,0.001 vs L6PED/PEA-15 NT.
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